Mechanisms of Dantrolene Neuroprotection in Alzheimer's Disease
Mechanisms of Dantrolene Neuroprotection in Alzheimer's Disease
批准号:
10570995
负责人:
HUAFENG WEI
金额:
$40.25万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-01 至 2024-12-31
关键词:
AD transgenic miceAffectAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease patientAlzheimer’s disease biomarkerAmyloidAmyloid beta-42Animal Disease ModelsAnimal ModelAutophagocytosisBiological MarkersBrainCalciumCell ProliferationCell SeparationCell membraneCell modelCell physiologyCellsClinicalClinical TreatmentClinical TrialsCognitionCytosolDantroleneDataDementiaDevelopmentDiseaseDisease modelEndoplasmic ReticulumFibroblastsFunctional disorderGlutamatesGlycine ReceptorsGoalsHippocampusHomeostasisHumanImpaired cognitionImpairmentInflammatoryIntranasal AdministrationMembraneMemory LossMessenger RNAMitochondriaMusMutationN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNerve DegenerationNeuritesNeurodegenerative DisordersNeurogliaNeuronal DifferentiationNeuronsOralPathologicPathologyPatientsPersonsPharmaceutical PreparationsProliferatingProteinsRisk FactorsRodentRyanodineRyanodine Receptor Calcium Release ChannelSiteSkinSynapsesTestingTransgenic AnimalsTransgenic MiceTransgenic OrganismsTreatment Efficacyadult neurogenesisamyloid pathologyantagonistapolipoprotein E-4cognitive functioncytokinedentate gyrusefficacy evaluationexperimental studyfamilial Alzheimer diseaseimprovedinduced pluripotent stem cellmigrationmouse modelnerve stem cellneurogenesisneuropathologyneuroprotectionpresenilin-1receptorside effectstem cellssynaptogenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Clinical trials for the treatment of Alzheimer's disease (AD) targeting amyloid have
largely failed. Ca2+ dysregulation may be an alternative mechanism. In familial AD (FAD),
calcium homeostasis is disrupted by over activation of NMDA (NMDAR) and ryanodine (RYR)
receptors leading to increased cytosolic calcium and subsequent cognitive dysfunction and
neuropathology. APOE4, a major risk factor for sporadic AD (SAD), also causes Ca2+
dysregulation related to NMDAR/RYR over activation. Dantrolene, a RYR antagonist and
clinically available drug, has been shown to mitigate amyloid pathology, neurodegeneration,
synaptic and memory loss in a FAD animal model. Our preliminary studies suggested that
intranasal dantrolene administration abolished memory loss in 5XFAD mice. Furthermore,
dantrolene promoted neuronal differentiation in induced pluripotent stem cells (iPSC) from
patients with either SAD with APOE4 or familial AD (FAD) by inhibition of RYR/NMDAR over-
activation. Our long term goal is to examine the efficacy of dantrolene to treat AD. The overall
objective of this study is to investigate the effects and underlying mechanisms of dantrolene on
adult neurogenesis in human and rodent SAD and FAD cells, as well as the effects of intranasal
dantrolene administration on adult neurogenesis and cognitive function in AD transgenic mice.
Our central hypothesis is that intranasal dantrolene inhibits the excessive activation of
RYRs and NMDARs in AD and promotes adult neurogenesis, improved cognitive function
and reduced AD neuropathology. We will test the hypothesis by the following specific aims.
Specific Aim 1. To determine the effects of dantrolene on RYR and NMDAR expression
and on cytosolic, mitochondrial, and ER Ca2+ concentrations and AD biomarkers in AD
stem cells using induced pluripotent stem cells (iPSC) from fibroblasts patients with either SAD
(APOE4 risk factor) or FAD (PSEN1 mutations), as well as neuroprogenitor cells (NPC) isolated
from E4FAD (APOE4+5XFAD) and 5XFAD transgenic Specific Aim 2. To examine the effects
of dantrolene on RYR and NMDAR activity, neurogenesis, proliferation, and the cellular
function of derived neurons and glia from AD cells. using the same cells as in SA1.
Specific Aim 3. To determine the effects of dantrolene on adult neurogenesis, cognitive
function, and neuropathology in animal models of AD. We expect that dantrolene will
promote adult neurogenesis and restore cognition and reduce AD pathology in AD mouse
models by alleviating the excessive activation of RYRs and/or NMDARs, especially with the
intranasal approach.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients.
氧疗法策略和技术治疗COVID-19患者缺氧的技术。
DOI:
10.26355/eurrev_202010_23248
发表时间:
2020-10
期刊:
European review for medical and pharmacological sciences
影响因子:
3.3
作者:
[]
通讯作者:
DOI:
10.1016/j.bja.2020.10.029
发表时间:
2021-03
期刊:
British journal of anaesthesia
影响因子:
9.8
作者:
[Wei H, Jiang B, Behringer EC, Hofmeyr R, Myatra SN, Wong DT, Sullivan EPO, Hagberg CA, McGuire B, Baker PA, Li J, Pylypenko M, Ma W, Zuo M, Senturk NM, Klein U]
通讯作者:
Klein U
DOI:
10.26355/eurrev_202104_25569
发表时间:
2021-04
期刊:
European review for medical and pharmacological sciences
影响因子:
3.3
作者:
[Wei H, Liang G, Vera RM]
通讯作者:
Vera RM
DOI:
10.1097/eja.0000000000001401
发表时间:
2021-03-01
期刊:
European journal of anaesthesiology
影响因子:
3.6
作者:
[Zha B, Wu Z, Xie P, Xiong H, Xu L, Wei H]
通讯作者:
Wei H
DOI:
10.26355/eurrev_202010_23247
发表时间:
2020-10
期刊:
European review for medical and pharmacological sciences
影响因子:
3.3
作者:
[Jiang B, Liang S, Liang G, Wei H]
通讯作者:
Wei H
共 7 条
Mechanisms of Dantrolene Neuroprotection in Alzheimer's Disease
-
批准号:10343664
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2019
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of Dantrolene Neuroprotection in Alzheimer's Disease
-
批准号:10227272
-
项目类别:
-
资助金额:$33.28万
-
财政年份:2019
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:7929736
-
项目类别:
-
资助金额:$14.78万
-
财政年份:2009
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of Anesthesia Mediated Neurotoxicity
-
批准号:9022481
-
项目类别:
-
资助金额:$32.35万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:7690355
-
项目类别:
-
资助金额:$27.56万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:8306165
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:7504657
-
项目类别:
-
资助金额:$27.56万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:8113131
-
项目类别:
-
资助金额:$27.18万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:8264392
-
项目类别:
-
资助金额:$0.84万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Mechanisms of anesthesia mediaited neurotoxicity
-
批准号:7893633
-
项目类别:
-
资助金额:$27.29万
-
财政年份:2008
-
负责人:HUAFENG WEI
-
依托单位:
Volatile anesthetics, calcium homeostasis and apoptosis
-
批准号:7057847
-
项目类别:
-
资助金额:$12.79万
-
财政年份:2005
-
负责人:HUAFENG WEI
-
依托单位:
Volatile anesthetics, calcium homeostasis and apoptosis
-
批准号:6859612
-
项目类别:
-
资助金额:$12.79万
-
财政年份:2005
-
负责人:HUAFENG WEI
-
依托单位:
Volatile anesthetics, calcium homeostasis and apoptosis
-
批准号:7596179
-
项目类别:
-
资助金额:$12.79万
-
财政年份:2005
-
负责人:HUAFENG WEI
-
依托单位:
Volatile anesthetics, calcium homeostasis and apoptosis
-
批准号:7386006
-
项目类别:
-
资助金额:$12.79万
-
财政年份:2005
-
负责人:HUAFENG WEI
-
依托单位:
Volatile anesthetics, calcium homeostasis and apoptosis
-
批准号:7215168
-
项目类别:
-
资助金额:$12.79万
-
财政年份:2005
-
负责人:HUAFENG WEI
-
依托单位:
海外基金